Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
NEW YORK, Feb. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutica
New class action for Ultragenyx (RARE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/6/2026.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ultragenyx To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - February 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragen
New York, New York--(Newsfile Corp. - February 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragen
NEW YORK and NEW ORLEANS, Feb. 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pha
SAN DIEGO--(BUSINESS WIRE)---- $RARE #RARE--Ultragenyx allegedly misled investors about setrusumab's potential Phase 3 study success in reducing fracture rates.
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
06:47pm, Friday, 13'th Feb 2026
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
03:00pm, Friday, 13'th Feb 2026
LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (
Why Is Ultragenyx Stock Sinking Friday?
01:21pm, Friday, 13'th Feb 2026
“The year ahead marks an important turning point for the company, as we approach two potential product launches and a pivotal data readout that, together, could significantly accelerate our commerci
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
11:25am, Friday, 13'th Feb 2026
RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.
New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultrageny
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutica
Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say
07:01pm, Thursday, 12'th Feb 2026
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall S
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such i
